Dr Adam Sharp
Honorary Consultant in Medical Oncology BSc BM PhD MRCP
Specialism: Drug development, Urology
Available at: Sutton
- Advanced prostate cancer
- New anti-cancer drugs
- Clinical trials
Dr Adam Sharp is Leader of the Translational Therapeutics Team and Honorary Consultant Medical Oncologist within the Prostate Cancer Targeted Therapies Group and Drug Development Unit at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research.
He initially trained as a Biochemist and Pharmacologist graduating from the University of Southampton with a 1st class honours degree and the Gerald Kerkut Prize in 2001. Following this he was awarded a Breast Cancer Campaign funded PhD studentship between 2002 and 2005 which developed his interest in cancer drug discovery and development at the Cancer Research UK Clinical Research Unit (Southampton).
At this juncture, he returned to the University of Southampton to study medicine. Having completed his medical degree in 2009 he trained in London and achieved his Membership of the Royal College of Physicians (MRCP) in 2012. Following which he was successful in obtaining a position as a Specialist Registrar in Medical Oncology at the Royal Marsden Hospital NHS Foundation Trust in 2013.
During his Specialist Registrar he has been successfully supported as an Academic Clinical Lecturer (National Institute for Health Research) and more recently as a Clinical Research Training Fellow (Medical Research Council), which has allowed him to work with Professor de Bono and his team since 2015.
Dr Sharp is focussed on developing novel therapeutic strategies (from bench to bedside) for the treatment of advanced prostate cancer and he has published and presented work within this field. His work has been recognised with research awards from the Royal Society of Medicine, Academy of Medical Sciences and American Society of Clinical Oncology. Most recently he has been awarded a Prostate Cancer Foundation Young Investigator Award and Wellcome Trust Clinical Research Career Development Fellowship.
The work of his team is focused on identifying novel therapeutic strategies to prevent the development of treatment resistance and to overcome the progression of cancer.